Sells mechanical infusion systems, including syringe drivers, needle sets and tubing, to pharmaceutical companies, specialty pharmacies and home-infusion providers.
10-K for FY2025, filed Mar 12, 2026KORU Medical develops, manufactures and commercializes innovative and patient-centric large volume subcutaneous infusion solutions…View ↗
Our revenues are derived from three business sources: (i) domestic core (which consists of US and Canada), (ii) international core, and…View ↗
SALES AND DISTRIBUTIONView ↗
Specialty pharmacies, home infusion providers, and distributors are our primary sales contacts, although we provide education and training…View ↗
KORU sells pumps, tubing and needles, with sales counted when products ship; biopharmaceutical companies also buy trial products and pay for engineering, testing and registration work as that work progresses.
10-K for FY2025, filed Mar 12, 2026Our revenues are derived from three business sources: (i) domestic core (which consists of US and Canada), (ii) international core, and…View ↗
For Product Revenue, we recognize revenues when shipment occurs, and at which point the customer obtains control and ownership of the…View ↗
We recognize NRE revenue under an input method, which recognizes revenue on the basis of our efforts or inputs (for example, resources…View ↗
$41.1M
10-K for FY2025, filed Mar 12, 2026
$41.1M ↗
Sales run both directly and through medical-device distributors; most products go through distributors so specialty pharmacies can use remote inventory management and one-stop shopping.
10-K for FY2025, filed Mar 12, 2026The FREEDOM System is sold through both direct sales and medical device distributors to pharmaceutical companies, specialty pharmacy…View ↗
No. It lost $2.6M in FY2025.
10-Q for Q3 FY2026, filed Nov 10, 2026
$218.1KView ↗
8-K, filed Mar 16, 2026
Linda Tharby, President and Chief Executive Officer of KORU Medical Systems, Inc. (the “Company”), has announced her retirement as Chief…View ↗
Growing. Revenue grew 75% in 4 years, from $23.5M in FY2021 to $41.1M in FY2025, about 15% a year.
Loading...